RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories

MONSEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Revance Therapeutics, Inc. (Nasdaq: RVNC) ("Revance") to Crown Laboratories, Inc. ("Crown") for $6.66 per share in cash in a tender offer. The sales price is substantially below the price target for Revance of multiple Wall Street analysts, including Stacy Ku of TD Cowen with a price target of$25.00 per share, and Annabel Samimy of Stifel Nicolaus with a price target of ...